Inhibitory effect of selenomethionine on carcinogenesis in the model of human colorectal cancer in vitro and its link to the Wnt/β-catenin pathway*

Edyta Korbut1,2, Agata Ptak-Belowska and Tomasz Brzozowski

Department of Physiology, Jagiellonian University Medical College, Kraków, Poland

Selenium compounds have been implicated as anticancer agents; however, the mechanism of their inhibitory action against cancer development has not been extensively investigated. A constitutive activation of the Wnt/β-catenin pathway is a central event in colorectal carcinogenesis. In this pathway, excessive cell proliferation is initiated by generation of β-catenin followed by overexpression of proto-oncogenes, such as c-Myc. It is believed that under physiological conditions the level of c-Myc is efficiently controlled by accessibility of the β-catenin protein through the process of phosphorylation by glycosyl synthase kinase 3β (GSK-3β). Here, we determined whether selenomethionine (SeMet) can inhibit cell growth and affect the Wnt/β-catenin pathway in the HT-29 human colorectal cancer cells in vitro. The effective cytotoxic doses of SeMet have been selected after 48 h of incubation of this compound with colorectal cancer HT-29 cell lines. MTT assay was used to assess cell viability and the protein and mRNA levels of β-catenin and c-Myc were determined by Western blotting and qPCR, respectively. SeMet potently inhibited growth of HT-29 cells, significantly decreased level of the β-catenin protein and mRNA concentration, down-regulated the c-Myc gene expression and up-regulated the pro-apoptotic Bax protein level. Moreover, SeMet increased the level of GSK-3β phosphorylated at serine 9 (S9) and significantly increased the level of β-catenin phosphorylated at S33 and S37. We conclude that SeMet suppresses growth of HT-29 colorectal cancer cells by a mechanism linked to the Wnt/β-catenin pathway, however, degradation of β-catenin may occur independently of GSK-3β catalytic activity and its phosphorylation status.

Key words: colorectal cancer, GSK-3β, Wnt/β-catenin pathway, selenium, selenomethionine

INTRODUCTION

Over the last few decades convincing evidence has been accumulated indicating that selenium compounds are good candidates for cancer treatment and chemoprevention. However, despite promising results, there is still little information available on the molecular genetics background underlying anti-tumorigenic effects of these compounds. The cellular responses induced by selenium in experimental models are very diverse and may depend on different forms and doses of this microelement (Brozmanova et al., 2010). Major dietary selenium compounds are the following amino acids: selenomethionine (SeMet), selenocysteine and Se-methylselenocysteine (Combs et al., 1998; Rayman, 2000; Brozmanova et al., 2010; Korbut et al., 2012). For instance, SeMet has been shown in numerous cancer models to inhibit neoplastic cell growth (Nelson et al., 2005; Goulet et al., 2007). It has been also reported that SeMet is less toxic than other selenium compounds, making it the selenium derivative form of choice for human interventional trials (Redman et al., 1997). Moreover, unlike selenite and selenocysteine, SeMet failed to exhibit glutathione peroxidase (GPx) activity known to protect the cells from oxidative damage. This clearly suggests that cytotoxic activity of SeMet involves a different mechanism, in part unrelated to antioxidative activity of this compound (Beutler et al., 1975). This was also confirmed by meta-analysis in an animal model which revealed that selenium-enriched diet showed greater potency in increasing GPx activity than SeMet (Birmingham et al., 2014).

One of the most attractive targets for anti-cancer therapy seems to be the Wnt/β-catenin pathway. An abnormal activation of this signalling pathway has already been described in a wide variety of human cancers (Kikuchi, 2003; Anastas et al., 2013; Han et al., 2013). Interestingly, over 90% of colorectal cancers have demonstrated abnormal regulation of the Wnt/β-catenin signalling (Fevr et al., 2007; Polakis, 2012).

The level of β-catenin, the central signalling protein of the Wnt/β-catenin pathway, is regulated by the activity of a destruction complex that is composed of the Axin scaffold protein, the adenomatosis polyposis coli protein (APC), casein kinase 1 (CK1), and the glycosyl synthase kinase 3β (GSK-3β). In the absence of Wnt signalling, GSK-3β sequentially phosphorylates β-catenin at S33 and S37, resulting in β-catenin recognition by β-TrCP, an E3 ubiquitin ligase subunit, and subsequent β-catenin ubiquitination and proteasomal degradation (He et al., 2004) (Fig. 1, left panel). In turn, in the presence of Wnt signalling, β-catenin accumulates in the cytoplasm and then it can translocate into the nu-

---

*List of abbreviations (partially):
- APC: adenomatosis polyposis coli protein
- CK1: casein kinase 1
- Axin: Axin scaffolding protein
- APCmin: adenomatosis polyposis coli protein (APC), casein kinase 1 (CK1), and the glycosyl synthase kinase 3β (GSK-3β)
- β-TrCP: β-transducin repeats-containing protein
- Wnt, Wingless + Integration-1 (Wg + INT-1)
- TCF/LEF: T-cell factor/lymphoid enhancer-binding factor
- Wnt/β-catenin pathway
- GPx: glutathione peroxidase
- GSK-3β: glycogen synthase kinase 3β
- β-TCP: β-transducin repeats-containing protein
- TCF: T-cell factor
nucleus. The nuclear β-catenin interacts with transcription factors – TCF/LEF, enhancing expression of c-Myc and other genes. The activity of GSK-3β is silenced by phosphorylation at S9. This phosphorylation induces a pseudo-substrate conformation in the substrate docking motifs of GSK-3β that acts as a competitive inhibitor for true substrates (Doble, 2003; McCubrey et al., 2014). These events play a pivotal role in the control of cell proliferation, differentiation and cell apoptosis (Clevers, 2006; Pecina-Slaus, 2010; Miller et al., 2012) (Fig. 1, right panel). Moreover, elevated β-catenin mRNA levels which correlate with constitutively high amounts or nuclear localization of β-catenin, were found in several tumors, including colorectal carcinomas (Bandapalli et al., 2009). The link between the Wnt signalling and apoptosis has become increasingly established in the literature (Pecina-Slaus, 2010). The Bcl-2 and Bax family of proteins play an important role in the regulation of the programmed cell death known as apoptosis. While Bcl-2 promotes cell survival, the structurally similar Bax induces programmed cell death by permeabilization of the outer mitochondrial membrane. Impairment of apoptosis is generally accepted as the central event in the mechanism of cancer development and seems to be responsible for tumour resistance to cytotoxic therapeutics (Adams et al., 2007).

In view of the above, we designed our study to determine the effect of SeMet on colorectal cancer cell proliferation, and Bax-mediated apoptosis, and we examined whether Wnt/β-catenin is involved in these effects of SeMet on cancer cells in vitro.

MATERIALS AND METHODS

Cell lines. Human epithelial colorectal adenocarcinoma cell line (HT-29) was purchased from European Collection of Animal Cell Cultures (ECACC) (Salisbury, UK). HT-29 cell line was maintained in RPMI 1640 medium (with L-glutamine and sodium bicarbonate) from Sigma-Aldrich (St. Louis, MO, USA) supplemented with 10% (v/v) foetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA). Human keratinocyte cell line (HaCaT) was purchased from CLS Cell Lines Service GmbH (Heidelberg, Germany). HaCaT cell line was maintained in high glucose DMEM medium (with 2 mM L-glutamine) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% (v/v) FBS (Sigma-Aldrich, St. Louis, MO, USA). Both cell lines were cultured in the presence of 1% (v/v) antibiotics/antimycotics solution (10 000 units of penicillin, 10 mg streptomycin, and 25 μg of amphoterecin B per mL) from Sigma-Aldrich (St. Louis, MO, USA), in a humidified incubator with 5% CO₂ at 37°C. Subculturing was done at subconfluent densities with a solution of 0.25% Trypsin-EDTA solution (Life Technologies/Thermo Fisher Scientific, Waltham, MA, USA) for 2 minutes at 37°C.

Tetrazolium-based growth assay (MTT). The growth inhibitory effect of SeMet on cellular viability was evaluated by the MTT colorimetric method using thiazolyl blue tetrazolium bromide (Sigma-Aldrich, St. Louis, MO, USA). HT-29 cells were plated in 5 replicates in 96-well plates at a density of 1 × 10⁴ cells/well in a final volume of 100 μL medium. After overnight incubation at 37°C, 5% CO₂, dilutions of SeMet were added in 5 replicates per drug concentration. Untreated cells (appropriate volumes of medium added) served as controls. After 48 h incubation, 50 μL of the MTT solution was added to each well and incubated for 4 h at 37°C. Medium was removed and the formazan product of MTT reduction was dissolved in 75 μL of DMSO per well. The optical density was measured at 550 nm. Each assay was repeated three times. Nonlinear regression graph was plotted between percentage of cell inhibition and log concentration, and IC₅₀ was determined using the GraphPad Prism software (Version 5.01, GraphPad Software, Inc., San Diego, CA, USA).

Selenomethionine treatment. SeMet (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in medium to a stock concentration of 10 mM. At 48 h before the SeMet treatment, exponentially growing human colon cancer cells were seeded at a density of 1 × 10⁴ cell/well. 24 h before the experiment, supplemented medium was replaced with a serum-free medium. SeMet concentration range and incubation time used in the study presented here were based on the results of a pilot studies. Control cells were treated with an equivalent volume of a serum free medium only.

Gene expression. Total RNA was isolated from cell samples using the SV Total Isolation Kit (Promega Fitchburg, Wisconsin, USA), according to the manufacturer’s instructions. The RNA concentration of each sample was measured using the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, Waltham, MA, USA).

The purity of extracted total RNA was determined by the A260/A280 ratio. cDNA was synthesized by reverse
transcription of 500 ng of total RNA from each sample, using MMLV First-Strand Synthesis Kit (GeneDireX, Las Vegas City, NV, USA) according to the manufacturer’s protocol. The reaction was performed in a T3 Thermocycler (Biotek, Göttingen, Germany). Relative gene expression was determined by qPCR according to the MIQE guidelines. The PCR primers and TaqMan probes for HPRT (a housekeeping gene, assay ID Hs99999909_m1), c-Myc (assay ID Hs00153408_m1) and β-catenin (assay ID Hs00355049_m1) were purchased from Life Technologies/Thermo Fisher Scientific (Waltham, MA, USA). The qPCR conditions were as follows: an initial incubation at 50°C for 2 min, then a denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Temperature cycling and real-time fluorescence measurements were done by using RotorGene RG-3000 Corbett Research thermal cycler (Qiagen, Hilden, Germany). The relative quantitation of gene expression was done by using the 2^ΔΔCT method. Each qPCR experiment was done in quadruplicate (two duplicates from two different reverse transcription reactions), and the mean Ct value was used for data analysis.

Western Blotting Analysis. Whole cell lysates were used in Western blotting analysis. Protein content was determined using the Bradford assay with an Ech808 (BioTek, Winooski, VT, USA) microtiter plate reader. Proteins were separated on NuPage Novex 10% Bis-Tris polyacrylamide electrophoresis gels (Invitrogen Ltd, Paisley, UK). After electrophoresis, proteins were transferred from gels onto nitrocellulose membranes by using an iBlot Dry Blotting System (Invitrogen Ltd, Paisley, UK). The primary antibodies used for detection were anti-β-catenin rabbit polyclonal antibody (1:4000), anti-β-catenin (phospho S33+S37) rabbit polyclonal antibody (1:1000), anti-GSK-3β (phospho S9) rabbit polyclonal antibody (1:4000), and anti-Bax rabbit polyclonal antibody (1:1000). Secondary antibodies were goat polyclonal antibodies to rabbit IgG H&L (HRP). As a control for protein loading, an anti-β actin rabbit polyclonal antibody (1:5000 dilution) was used. All antibodies were obtained from Abcam (Cambridge, UK). Signals for protein bands were visualized by SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s protocol, and exposed to X-ray film (KODAK, Rochester, MN, USA). The density of each specific band was measured using a computer-assisted imaging analysis system.

Statistical Analysis. Results are presented as the mean values ± S.D. Statistical differences of data for two groups were compared by unpaired Student’s t-test. Relative expression levels from qPCR were logarithmically transformed prior to statistical analysis for normalization. For all statistical analyses, the level of significance was set as P<0.05. The IC50 values were calculated by using the GraphPad Prism® 5 software (Version 5.01, GraphPad Software, Inc, San Diego, CA, USA).

RESULTS

The effect of SeMet administration on HT-29 and HaCaT cell viability

We investigated the effect of SeMet on the viability of HT-29 colon cancer cells and normal human keratinocytes HaCaT, and selected SeMet cytotoxic/antiproliferative concentrations for further experiments. The HaCaT cell line was used in order to get more insights as to whether SeMet can affect the cancerogenic HT-29 and non-cancerogenic (HaCaT) cell lines. The cell lines were exposed to SeMet for 48 h and MTT growth assay was performed. SeMet sensitivity values were calculated in terms of 50% inhibitory concentration (IC50). We observed that SeMet causes a concentration-dependent inhibition of HT-29 growth, with an IC50 value of 283 µM (n=3) after 48 h of incubation with this derivative of selenium containing amino acid (Fig. 2). In contrast, IC50 for SeMet in HaCaT cells was 630 µM (Fig. 3).

SeMet decreases expression and protein levels of β-catenin

To ascertain if β-catenin is a critical factor in the anti-cancerogenic effect of SeMet, we analysed the level of this protein by Western blotting in the HT-29 cell line after 48 h of incubation of these cells with SeMet at cytotoxic doses (IC50, IC25). The β-catenin was used to normalize the changes in the β-catenin signal. As shown in Fig. 4, incubation with SeMet at the dose of IC25 tended to decrease the level of β-catenin protein but this change was not significant. However, when the IC50 dose of Se-
Met was applied, a marked decrease (approx. 2 fold vs control) in β-catenin protein was observed. Similar results with SeMet were obtained at mRNA level as assessed by qPCR. As shown in Fig. 5, the relative gene expression of β-catenin significantly decreased in the SeMet-stimulated HT-29 cells when compared to untreated control cells.

**SeMet inhibits c-Myc gene expression**

To determine whether SeMet can influence c-Myc gene expression, HT-29 cell line was incubated with SeMet at cytotoxic concentrations (IC₅₀, IC₅₀) and the mRNA level was investigated by qPCR. As shown in Fig. 6, the relative gene expression of c-Myc was significantly decreased (approx. 12 fold for IC₅₀ vs control) in the SeMet stimulated HT-29 cells when compared with the untreated control. These data suggest that SeMet can inhibit the growth of HT-29 cells by inhibiting c-Myc gene expression.

**Inhibition of β-catenin is due to its enhanced degradation and does not depend on GSK-3β S9 phosphorylation status**

On the basis of our previous observations we found that β-catenin is down-regulated by SeMet within 48 h in colorectal cancer cell line which can result from an increased degradation of β-catenin. We observed that at cytotoxic concentrations, SeMet had increased β-catenin phosphorylation at the S33 and S37 residues (approx. 2 folds vs control; Fig. 7), and subsequently resulting in β-catenin proteasomal degradation. To determine the mechanism of β-catenin phosphorylation by SeMet, involvement of GSK-3β was evaluated. Treatments with SeMet significantly increased the level of phosphorylated GSK-3β in HT-29 cells (approx. by 2 folds and 6 folds vs control for IC₂₅ and IC₅₀, respectively) (Fig. 8). These results indicate that SeMet caused an increase in β-catenin phosphorylation in the colorectal cancer cells and this effect appears to be independent of GSK-3β phosphorylation at S9.

**SeMet increases pro-apoptotic Bax protein level**

The level of Bax protein with or without incubation with SeMet was examined in order to determine the potential pro-apoptotic activity of this seleno-derivative of...
DISCUSSION

Selenium is an essential trace element in mammals and is usually ingested with food or dietary supplementation either in an organic or an inorganic form (Rayman, 2000; Carroll et al., 2015). Although the effect of anti-cancer action of selenium still remains unexplored, several mechanisms, such as antioxidant protection, inhibition of cancer cell growth, modulation of cell cycle and an increase in apoptosis, have been proposed to explain its anti-neoplastic activities (Brozmanova et al., 2010). Recent studies suggest that at concentrations higher than nutritional requirements, selenium exerts anti-cancer potential and can be used not only for cancer prevention but also for treatment of cancer growth (Brozmanova et al., 2010).

The organic selenium compounds, such as SeMet, are predominant forms of selenium which are considered as more bioavailable than its inorganic forms (Menter et al., 2000). That is why our major goal was to determine the effect of SeMet on colon cancer cells and to elucidate if Wnt/β-catenin pathway could be a molecular target for this agent. To the best of our knowledge, no data have been previously reported on the role of SeMet on Wnt/β-catenin pathway in the HT-29 colon cancer cells. According to the recent evidence, reduced β-catenin expression is involved in induction of cell death by various drugs and nutritional factors, including non-steroidal anti-inflammatory drugs (NSAIDs) and butyrate (Smith et al., 2000; Bordonaro et al., 2002; Emanuelse et al., 2004). Rao et al. reported that a synthetic organoselenium compound, p-XSC, significantly suppresses β-catenin expression in intestinal polyps in the APCmin mouse (Rao et al., 2000). In another study, p-XSC also decreased protein levels of β-catenin in colon cancer cells (Narayanan et al., 2004).

Here, we provide direct evidence that selenium, in the form of SeMet, exerts anti-proliferative activity against the HT-29 cell line. The mean IC50 value for HT-29 cells was 283 µM at exposure durations of 48 h. Similar results were reported by Redman et al., who found that SeMet inhibits growth of human tumour cell lines at concentrations within the micromolar (µM) range and in a dose-dependent manner (Redman et al., 1998). They also demonstrated that the sensitivities of tumour and normal cells to SeMet were highly diverse. This is consistent with our findings. We observed that the cytotoxic dose (IC50) of SeMet for normal human keratinocyte (HaCaT) cell line was approx. 2 folds higher than for the tumour HT-29 cells (IC50 = 630 µM).

Furthermore, we found that administration of SeMet at effective anti-proliferative doses had significantly decreased β-catenin level in the HT-29 cell lysates. Moreover, this effect was accompanied by down-regulation of c-Myc mRNA. Similarly, Zeng et al. reported that submicromolar concentrations of methylselenic acid, generated by incubating methionase with SeMet, inhibited c-Myc expression in the HT1080 fibrosarcoma cells (Zeng et al., 2009). In turn, studies conducted by Zhang et al. revealed that c-Myc mRNA and protein levels were significantly decreased upon methylseleninic acid (MSA) treatment in human oesophageal squamous cell carcinoma cell lines.
et al., 2009). On the other hand, Liu et al., 2010). This is compatible with our observation.

...25...β...P...et al., 2014). Our data...β...et al., 2002).

To determine whether the decrease in β-catenin protein level resulted from an increase in its degradation, the phosphorylation of β-catenin and GSK-3β was evaluated in the presence and absence of SeMet. The β-catenin protein level is normally kept low by its phosphorylation at S33 and S37, mediated by GSK-3β, which results in the β-catenin targeting for proteasomal degradation. The presence of Wnt blocks phosphorylation, thereby allowing β-catenin to accumulate and translocate into the nucleus, where it co-operates with several transcription factors (Gao et al., 2014). Our data indicate that SeMet resulted in an increase in β-catenin phosphorylation (at S33 and S37 residues, as commonly recognized), thus, showing that cytotoxic doses of SeMet can promote β-catenin degradation. Moreover, we found a significant reduction in β-catenin mRNA after SeMet treatment. However, mechanisms underlying this effect remain unclear to us. Bandapalli et al. provided several lines of evidence that β-catenin can induce transcription from its own promoter, thereby up-regulating its expression. Thus, they considered β-catenin as a positive feedback activator for Wnt/β-catenin signaling (Bandapalli et al., 2009).

Taking this notion into consideration, it is possible that SeMet reduces β-catenin gene expression and this effect is responsible for β-catenin-protein down-regulation observed in our study. On the other hand, according to Ebert et al., regulation of β-catenin transcription through β-catenin itself seems unlikely, since the β-catenin promoter does not contain a TCF-responsive element. The above, however, does not change the fact that β-catenin transcription might be regulated by other transcription factors which are triggered by the β-catenin-TCF/LEF complex (Ebert et al., 2002).

It has been clearly established that phosphorylation at S9 correlates with inhibition of the GSK-3β activity (McCubrey et al., 2014). However, involvement of GSK-3β phosphorylation in Wnt signalling remains unexplored and has not been carefully studied thus far (Gao et al., 2014). Our present findings provide an alternative to the widely accepted molecular mechanism for regulation of cytoplasmic β-catenin by activation of β-catenin degradation pathway. Interestingly, we found that β-catenin protein down-regulation was accompanied by simultaneous phosphorylation of GSK-3β at S9 upon SeMet treatment. This remains at odds with the observation of Saifo et al. who reported that administration of methyl selenoc acid (MSeA) had no significant effect on the level of total GSK-3β (in HT-29 or HCT-8) and failed to alter the phosphorylation level of β-catenin (S33 + S37 + T41) in colorectal and colon cancer cell cultures, and this alteration was mediated by simultaneous increase in GSK-3β phosphorylation. However, no changes in GSK-3β phosphorylation level were observed in normal embryonic kidney cells (HEK 293) (Dihlmann et al., 2003). Their results, demonstrating that aspirin can elevate GSK-3β phosphorylation at S9 in colon cancer cells, suggest that NSAIDs might stabilize selected S/T-phosphorylation by inhibiting a phosphatase known to revert proteins into their unphos-
phosphorylated forms (Dihlmann et al., 2003). Thus, it cannot be excluded that in our studies SeMet triggered the Wnt/β-catenin in a similar manner as previously described, and SeMet might indirectly inactive specific phosphatases targeting β-catenin and GSK-3β. However, the proposed mechanism remains to be elucidated in further studies.

The GSK-3β plays pivotal roles in cancer development which remain complex and are still controversial (McCubrey et al., 2014). GSK-3β is overexpressed in many tumour types including: colon, liver, ovarian and pancreatic tumours (McCubrey et al., 2014). Besides promoting β-catenin proteasome degradation, it can phosphorylate and stabilize Wnt-coreceptor LRPs/6 which fosters β-catenin signalling. Consequentially, inhibitors of this kinase could arrest β-catenin-mediated gene expression and may eventually be used in treatment of certain cancers (McCubrey et al., 2014). Zhou et al. demonstrated that suppression of GSK-3β inhibited pancreatic cancer growth and angiogenesis (Zhou et al., 2012). Similarly, treatment of leukaemia cell lines with a GSK-3β inhibitor resulted in GSK-3β S9 phosphorylation, β-catenin stabilization, cyclin B down-regulation, inhibition of cell growth, cell cycle arrest at G2/M, and promotion of apoptotic cell death (Mirilashvili et al., 2012). Interestingly, according to Tan et al., GSK-3β inhibition promotes p53-dependent apoptosis through a Bax-mediated mitochondrial pathway. They noticed that a modulation of GSK-3β by inhibitors (LY2119301 and lithium) was able to convert the p53 response from growth arrest to apoptosis. In their opinion, increased S9 phosphorylation of GSK-3β by LY2119301 or lithium could displace Bax, promoting its activation and cell death (Tan et al., 2005). Therefore, in agreement with these studies, we provided evidence that SeMet was able to up-regulate pro-apoptotic Bax, suggesting that this effect can be mediated by an increased S9 phosphorylation of GSK-3β.

In summary, we hypothesize that GSK-3β phosphorylation at S9 may not be the limiting component for Wnt-signalling in colon cancer cells. Even more, GSK-3β inhibition, resulting from SeMet treatment, may function as a tumour suppressor and can promote apoptotic cell death.

CONCLUSIONS

Our studies revealed that SeMet inhibits growth of the HT-29 colon cancer cell line by targeting the Wnt/β-catenin pathway and this is, at least in part, to an increase in the Bax-mediated apoptosis. However, the latter requires confirmation in further studies conducted under in vitro and in vivo conditions. We conclude that β-catenin and GSK-3β appear to act as key targets for SeMet in colorectal cancer cells, leading to down-regulation of c-Myc gene expression. Moreover, SeMet-induced β-catenin degradation seems to occur independently of the status of GSK-3β catalytic activity and S9 phosphorylation (Fig. 10).

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We acknowledge financial support from the project Interdisciplinary PhD Studies “Molecular sciences for medicine” (co-financed by the European Social Fund within the Human Capital Operational Programme).

REFERENCES

Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324–1337. doi: 10.1038/sj.onc.1210220

Anastas NJ, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13: 11–26. doi: 10.1038/nrc3419

Bandapalli OR, Dihlmann S, Helwa R, Macher-Goeppinger S, Weitz J, Schirmacher P, et al. (2009) Transcriptional activation of the beta-catenin gene at the invasion front of colorectal liver metastases. J Pathol 218: 370–379. doi: 10.1002/path.2539

Bermingham EN, Hesketh JE, Sinclair BR, Koolaad JP, Roy NC (2014) Selenium-enriched foods are more effective at increasing glutathione peroxidase (GPx) activity compared with selenomethionine: a meta-analysis. Nutrients 6: 4002–4031. doi: 10.3390/nu6104002

Beutler E, Beutler B, Matsumoto J (1975) Glutathione peroxidase activity of inorganic selenium and seleno-DL-cysteine. Experimental 31: 760–770

Bordonoaro M, Lazarova DL, Auglerith LH, Sartorelli AC (2002) Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer 97: 42–50

Brezmanova J, Manikova D, Vickova V, Chovanec M (2010) Selenium: a double-edged sword for defense and offense in cancer. Arch Toxicol 84: 919–938. doi: 10.1007/s00204-010-0595-8

Carroll I, Davies MJ, Pattison D (2015) Reaction of low-molecular mass organoselenium compounds (and their sulphur analogues) with inflammation-associated oxidants. Free Radic Res 49: 750–767. doi: 10.1080/10715762.2015.1018247

Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480. doi: 10.1016/j.cell.2006.10.018

Combs GF, Jr., Gray WP (1998) Chemopreventive agents: selenium. Pharmacol Ther 79: 179–192

Dihlmann S, Klein S, von Knobbel Doechert M (2003) Reduction of beta-catenin/β-cell transcription factor signaling by aspirin and in domethacin is caused by an increased stabilization of phosphorylate beta-catenin. Mol Cancer Ther 2: 509–516. doi: 10.1016/j.cell.2006

Doble BW (2003) GSK-3: tricks of the trade for a multi-tasking kinase. Pharmacol Ther 97: 1175–1186. doi: 10.1016/j.pharmthera.2003.07.018

Ebert MP, Fei G, Kabamin S, Muller O, Yu J, Sung JJ, et al. (2002) Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23: 87–91

Emanuelle S, D’Anneo A, Bellavia G, Vassallo B, Lauricella M, De Blasio A, Vento R, Tesorere G (2004) Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of beta-catenin, pB and B-ML. Eur J Cancer 40: 1441–1452. doi: 10.1016/lejca.2004.01.039

Fevr T, Rohine S, Lavuard D, Huelsken J (2007) Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Molecular and cellular biology 27: 7551–7559. doi: 10.1128/MCB.01034-07

Gao C, Xiao G, Hu J (2014) Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Bioi 4: 13. doi: 10.1186/2045-3701-4-13

Gouler AC, Watts G, Lord JL, Nelson MA (2007) Profiling of selenium-responsive genes in colon cancer by microarray analysis. Cancer Biol Ther 6: 494–501. doi: 10.4161/cbt.6.5.4241

Han Y, Park J, Park S, Hahn K, Hong S, Kim E (2013) Gastrin promotes intestinal polyposis through cholecystokinin-B receptor-mediated proliferative signaling and fostering tumor microenvironment. J Physiol Pharmacol 64: 420–437

He X, Senemov M, Tarnai K, Zeng X (2004) LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131: 1663–1677. doi: 10.1242/dev.011117

Kikuchi A (2003) Tumor formation by genetic mutations in the com ponents of the Wnt signaling pathway. Cancer Sci 94: 225–229

Koburz E, Prak-Belowska A, Brzozowski T (2012) Mechanisms promoting physiological cells progression into tumorigenesis. J Physiol Pharmacol 63: 565–579

Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, et al. (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenosomatous polyposis coli protein. Mol Cell 7: 927–936

McKeevy JA, Steelman LS, Bertrand FE, Davis NM, Sokolovsky M, Abrams SL, Montalto G, D’Assoro AB, Libra M, Nicoletti F, Maestro R, Basseck J, Rakus D, Gizak A, Demidenko Z, Cocco L, Mar tro J, Cervello M (2014) GSK-3 as potential target for therapeutic intervention in cancer. Onco Targets & 7: 2881–2911. doi: 10.18632/oncotarget.2037

Menter DG, Sabichi AL, Lippman SM (2000) Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9: 1171–1182

Miller D, Thomas SD, Jacobs K (2013) c-Myc and cancer metabolism. Clin Cancer Res 18: 5456–5533. doi: 10.1186/1078-0432.CCR-12-0797

Mirlashari MR, Randen I, Kjeldsen-Kragh J (2012) Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells
through mitochondria-dependent pathway. *Leukemia research* **36**: 499–508. doi: 10.1016/j.leukres.2011.11.013

Narayanan BA, Narayanan NK, Desai D, Pittman B, Reddy BS (2004) Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. *Carcinogenesis* **25**: 2443–2449. doi: 10.1093/carcin/bgh252

Nelson MA, Goulet AC, Jacobs ET, Lance P (2005) Studies into the anticancer effects of selenomethionine against human colon cancer. *Ann N Y Acad Sci* **1059**: 26–32. doi: 10.1196/annals.1339.016

Pecina-Slaus N (2010) Wnt signal transduction pathway and apoptosis: a review. *Cancer Cell Int* **10**: 22. doi: 10.1186/1475-2867-10-22

Polakis P (2012) Wnt signaling in cancer. *Cold Spring Harb Perspect Biol* **4**. doi: 10.1101/cshperspect.a008052

Rao CV, Cooma I, Rodriguez JG, Simi B, El-Bayomy K, Reddy BS (2000) Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene) selenocyanate. *Carcinogenesis* **21**: 617–621

Rayman MP (2000) The importance of selenium to human health. *Lancet* **356**: 233–241. doi: 10.1016/S0140-6736(00)02490-9

Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, et al. (1998) Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. *Cancer Lett* **125**: 103–110

Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al. (1997) Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. *Carcinogenesis* **18**: 1195–1202

Saifo MS, Rempinski DR, Jr., Rustum YM, Azrak RG (2010) Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. *Mol Cancer* **9**: 310. doi: 10.1186/1476-4598-9-310

Smith ML, Hawcroft G, Hall MA (2000) The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. *Eur J Cancer* **36**: 664–674

Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q (2008) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. *Cancer Res* **68**: 9012–9020. doi: 10.1158/0008-5472.CAN-05-1226

Zeng H, Wu M, Borten JH (2009) Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes. *J Nutr* **139**: 1613–1618. doi: 10.3945/jn.109.110320

Zhang W, Yan S, Liu M, Zhang G, Yang S, He S, Bai J, Quan L, Zhu H, Dong Y, Xu N (2010) beta-Catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. *Cancer Lett* **296**: 113–122. doi: 10.1016/j.canlet.2010.04.001

Zhou W, Wang L, Gou SM, Wang TL, Zhang M, Liu T, Wang CY (2012) ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. *Cancer Lett* **316**: 178–186. doi: 10.1016/j.canlet.2011.10.033